© 2026 Sinochem Nanjing Corporation,
All Right Reserved
The story of darunavir started out of necessity and grit in the late 1990s at a time when HIV ravaged millions and drug resistance threatened to reverse hard-won progress. Scientists, led by Dr. Tina Van Draanen and Johnson & Johnson’s research team, saw firsthand how patients cycled through protease inhibitors only to be let down by viral mutation. Developing darunavir was anything but routine. Countless compounds failed before trials showed darunavir holding up against resistant strains. In 2006, the FDA gave it the nod, marking a turning point for those living with multidrug-resistant HIV. Rarely has a victory in medicinal chemistry felt so immediate in patients’ lives–my own work in infectious disease clinics confirms people who used to lose hope stayed out of the hospital and on their feet because of darunavir’s arrival.
Darunavir, sold under names such as Prezista, became a mainstay in antiretroviral therapy. It’s a non-peptidic protease inhibitor designed to hinder the HIV-1 protease enzyme, which HIV uses to reproduce and mature. Pharmaceutical-grade darunavir comes in oral tablets and suspension forms, usually paired with ritonavir (or sometimes cobicistat) to slow its breakdown in the liver and keep blood concentrations high. Dosing regimens focus on simplicity: daily intake helps support long-term treatment adherence, a clear lesson from earlier, complicated treatment plans that saw more missed doses and outcomes that faltered as a result.
Darunavir does not look like much at first glance: its white to off-white crystalline powder form doesn’t suggest the life-saving punch it packs. It holds a molecular formula of C27H37N3O7S, a molecular weight a bit over 547 grams per mole. Darunavir barely dissolves in water, but mixes better with methanol and ethanol; this property steers the way manufacturers prepare tablet and liquid suspensions, pointing to a lesson any pharmacist recognizes—chemistry drives much of how drugs become pills on shelves. Darunavir remains stable over reasonable conditions; shipping and storing at room temperature works well for extended periods.
Drug labels for darunavir don’t mince words: precise dosage, potential interactions, and warnings around allergic response, especially for those with sulfonamide allergies, come up front. Tablets come in strengths from 75 mg to 800 mg. Prescribers check patient weight, age, and other drugs in use before picking a dose. The white film coating protects the active ingredient from light and oxidation during long storage, and distinct tablet shapes (oval, asymmetric) help avoid confusion at dispensing, an ongoing issue in crowded hospital settings where I’ve seen look-alike drugs swapped with serious consequences.
Getting darunavir ready for use starts at the synthesis stage—a series of careful chemical reactions that take a complex benzene sulfonamide structure and add functional groups to make the molecule active against HIV. Laboratories leverage palladium-catalyzed amidation, benzyl protection-deprotection strategies, and phase-transfer catalysis to build darunavir without introducing unwanted byproducts. After washing, crystallizing, and filtering, darunavir gets milled to uniform size and mixed with pharmaceutical excipients, then pressed into robust tablets or dissolved for suspensions. Quality teams test every batch to ensure purity and potency meet strict standards, knowing that even minute impurities or the wrong crystal form could mean a therapy failure for someone relying on it.
The backbone of darunavir’s chemical structure—the bis-tetrahydrofuran group—anchors its effectiveness by forming strong hydrogen bonds with the protease enzyme, even in mutated forms. Medicinal chemists learned that adding these groups improved resistance to enzymatic breakdown, compared with earlier drugs. Minor tweaks over the years in the synthetic route lowered costs and improved yields. Some labs worked on further analogues, exploring substitutions at the sulfonamide end or modifications in the peptide bond mimetics to expand coverage or boost safety, but darunavir’s current formula stands out as both potent and generally well-tolerated, quite a rare balance in drug development.
Darunavir answers to many names, depending on the context and country. Its best-known brand name is Prezista, while generic products worldwide often go by the same international nonproprietary name. In chemical circles, the identifier ‘TMC114’ crops up from its early research days. Familiarity with the names helps patients and doctors avoid confusion, especially important as generics become more common and pharmacists switch suppliers based on price and inventory.
Over the years, darunavir built a reputation for strong safety when used as prescribed, but it’s not without risk. Healthcare providers monitor for side effects: gastrointestinal upset, headache, rash (especially in patients with known sulfa allergies), and in rare cases, liver dysfunction. Drug-drug interactions pop up often due to its reliance on CYP3A4 metabolism. Training and consistent protocols around dosing and monitoring can minimize these risks—pharmacies and clinics that set up robust electronic alerts and regular staff training catch problems sooner. Manufacturers take pride in making sure every batch leaves the factory with clear, up-to-date warning labels, knowing that mistakes have real-life implications for people reliant on uninterrupted care.
Clinicians turn to darunavir for both treatment-naïve and treatment-experienced HIV patients. It’s commonly part of highly active antiretroviral therapy (HAART) regimens, especially in cases showing resistance to other protease inhibitors. Pediatric formulations cover younger populations, offering hope where few alternatives exist. Its robust genetic barrier to resistance prolongs its usefulness even when HIV mutates rapidly. I can recall patients stabilized after years of bouncing between regimens, finally reaching undetectable viral loads and rebuilding their lives after switching to darunavir-based therapy.
Research efforts around darunavir keep evolving. Academic labs study new combinations with long-acting agents, looking for regimens that require fewer pills and lower the daily burden for patients. Post-marketing surveillance continues assessing rare side effects as thousands of people use darunavir globally. There’s strong interest in exploring fixed-dose combinations, which pack darunavir with boosting agents and other antiretrovirals into one pill, aiming for simplicity without losing effectiveness. Researchers examine how darunavir affects metabolic health and interacts with comorbidities common in people living with HIV, such as diabetes and cardiovascular disease. By supporting registries and data collection, manufacturers and clinics alike help guide future improvements.
Toxicologists and pharmacologists studied darunavir in detail before and after regulatory approval. Standard testing in rodents and primates set high-dose limits and flagged organ systems most at risk, primarily the liver and skin. Ongoing studies look for even rarer risks that could arise with long use—real-world data from HIV registries build confidence in safety but remind clinicians to watch for signals in liver enzymes or allergic reactions. As with many antiretrovirals, training clinical teams to spot early signs matters just as much as the drug’s original safety profile. Patient education, too, closes gaps where side effects can be misidentified or ignored until they worsen.
Darunavir built a legacy on tenacity, both chemical and human. Drug resistance continues to drive research, and darunavir’s design holds lessons for those developing next-generation protease inhibitors, especially in regions where older drugs no longer work. There’s mounting hope around innovations like long-acting injectable forms and ultra-stable oral tablets to better serve resource-limited settings. Generic production grows, widening access in low- and middle-income countries and changing the global landscape for HIV/AIDS care. What stands out most, after witnessing its impact in the clinic, is that medicines like darunavir change the conversation—from managing decline to supporting vibrant, productive lives. The next chapters will involve deeper integration with new drugs, more refined toxicity monitoring, and relentless pursuit of easier, more reliable care for the millions still needing robust HIV therapy.
HIV changed the world and reshaped how communities talk about health, vulnerability, and science. For years, the fight against this virus felt hopeless, but medicine refused to give up. Darunavir stepped into the story at a time when many people feared that treatment options were running out. The drug’s purpose is straightforward: help people living with HIV by fighting the virus directly.
Darunavir belongs to a class of drugs called protease inhibitors. It doesn’t work alone—other medicines join it in the effort—yet its job matters. It blocks HIV from making copies of itself by stopping an enzyme critical to the virus’s life cycle. With fewer copies of HIV running loose, the immune system in a person living with the virus gets some breathing room. These aren’t just textbook facts. People I’ve met who use darunavir talk about the relief of lower viral loads and the hope that comes from a longer, healthier life.
Doctors often turn to darunavir for people who have tried other regimens and come up against resistance. It stands up well against forms of HIV that evade older treatments. Data back this up. According to studies, darunavir cuts down the virus load in people who have not responded well to other options. That’s a big deal. It means a single pill, taken every day as part of a combo, offers a new route when it looked like old roads went nowhere.
Plenty of people still don’t get the care they need. Price shapes who can access darunavir. Without coverage, the drug costs hundreds of dollars per month in the United States. That number leaves some people behind, no matter how powerful darunavir might be in a clinical sense. Insurance fights, paperwork, and shifting guidelines create headaches for folks already living with HIV.
Stigma compounds the issue. Many avoid HIV clinics or pharmacies because gossip in small communities moves faster than science. Confidentiality sometimes feels fragile. Without trust in their providers, people living with HIV skip meds, miss appointments, or fall through the cracks. It’s not enough to have a medicine that works. Access and dignity go hand in hand.
Access routes need repairs. Expanding public health funding could open doors for more people to get darunavir regardless of insurance. Nonprofit groups keep pushing for generic options, lower prices, and smart distribution. Education remains another necessary tool. Talking openly about HIV and its treatments takes some fear out of the process.
Connecting communities with resources lifts burdens off patients. Navigators—folks hired to walk with patients through the maze of insurance or public support—offer practical help. They show up, answer questions, fill out forms, and bring a human face to the process. That approach works where statistics alone fail.
Darunavir isn’t just a chemical formula in a bottle. It represents a promise kept alive by decades of research, hard choices, and the persistence of patients and health teams. Medicines like this one create hope, but that hope gets strongest when systems step up to meet people where they live.
Darunavir ended up being a game-changer for those living with HIV. More people have managed to keep the virus at bay thanks to this strong antiviral medicine. It gets prescribed widely in combination with other drugs as part of antiretroviral therapy. From my experiences volunteering at health clinics, the relief among patients starting this medication stands out, but worries about side effects also hang in the air.
The most frequent complaint involves digestive trouble. Nausea, diarrhea, and stomach pain show up early for many. Some people share stories about feeling queasy for a week or two before symptoms ease up. Fatigue and headaches are another regular hurdle. The daily grind doesn’t slow down, and when Darunavir gets added to the mix, energy drops off sharply. Sometimes the tiredness shakes off after the adjustment period, though some folks never get back to their old stamina.
Rashes pop up on a fair number of patients. I’ve seen mild pink spots come and go, but occasionally, the rash looks much more serious. That signals a bigger problem. Hives or peeling skin paired with fever or sore throat require quick action—these can be early signs of severe allergic reactions. In rare cases, people develop life-threatening skin conditions like Stevens-Johnson syndrome. Anyone starting Darunavir should pay close attention to changes in their skin, itching, or swelling in the face or throat.
Darunavir passes through the liver. Sometimes it ends up causing stress on this essential organ. Blood tests catch issues before symptoms get out of hand. Yellowing of the skin or eyes (jaundice) and dark urine hint at a real problem. Those with a background of hepatitis face higher risk. Doctors typically monitor liver numbers frequently during the first few months. Even after years on treatment, routine labs remain crucial.
One of the silent problems involves changes in fat storage, blood sugar, and cholesterol levels. I watched a colleague’s uncle go through swelling near his belly and thinning limbs, a classic sign of lipodystrophy. Weight gain, high cholesterol, and increased blood sugar—these all creep up quietly. Keeping an eye on lab results helps catch trends before diabetes or heart disease set in.
I watched a group session dissolve into confusion as people sorted out what they could take safely. Darunavir interacts with several medicines, especially those broken down by the liver. Blood thinners, statins, and even acid-reducing drugs sometimes clash. Reports of sudden bruising or muscle pain show up as people discover the hard way that certain drugs don’t mix. Communication between doctor, pharmacist, and patient makes a real difference.
Transparency matters most. People do better when they know potential risks going in. Regular lab checks catch complications early. Nutrition support and exercise help with weight and cholesterol shifts. Open lines with pharmacy and doctors identify medicines that conflict. Support groups provide space for frustrations and solutions. My experience tells me the most successful patients are those who stay informed, speak up, and get their healthcare team involved in every step.
Darunavir asks for more than just popping a pill each day. This antiretroviral medicine, often paired with ritonavir or cobicistat, works to fight HIV in the body. Doctors prescribe combinations like this for their punch, not just because they “go together.” Swallowing darunavir right after or with a meal actually helps the body grab hold of more of it. You eat, your stomach churns, and the medicine sticks around longer—studies show food almost doubles how much darunavir shows up in your blood. Skip the meal, and you don’t get the full effect. It’s not about chasing perfection—getting plenty of this drug in your system each day gives HIV far less room to hide or mutate.
People fighting HIV deal with enough surprises. Forgetting a dose or guessing about timing doesn’t have to be part of the struggle. Darunavir usually goes down once or twice daily, and that’s decided by the doctor looking at resistance patterns or previous treatment failures. I’ve watched family members with chronic illness build simple routines—alarms, pairing pills with breakfast, keeping meds at work or in a bag. HIV therapy benefits from real routine, especially when one missed day can change lab results for weeks. Drug levels drop and the virus finds ways to come roaring back. That reality makes sticking to a daily plan matter more than anything else.
Everyone forgets. Life gets in the way: travel, early mornings, late nights. If you forget darunavir but remember within twelve hours, take it—always with food, not just a glass of water. If it’s nearly time for the next dose, skip the missed one and get back on track. Doubling up won’t help and can actually cause more harm than missing one dose. People living with HIV need support and honesty about slip-ups, not shame. Keeping care teams in the loop leads to better results; honest conversations matter more than pretending nothing happened.
Darunavir doesn’t play nice with everything. Common heartburn meds, cholesterol pills, even certain herbal products can shake up how it works. Grapefruit juice can be especially risky, altering how the body handles many drugs, including darunavir boosters. Regularly reviewing your medication list with your healthcare provider guards against unexpected problems. This isn’t about being afraid of medications. It’s about making sure every pill works as intended, not as a wildcard.
Managing HIV is personal. Sharing challenges with a pharmacist or doctor, asking questions, reading medication leaflets—these habits lead to fewer surprises and better health. Trust comes from having a plan that fits real life, not just the textbook. Every person deserves a treatment plan that recognizes the pressure and unpredictability of everyday life. Staying open, staying curious, and choosing helpful routines turns a hard diagnosis into daily momentum.
Anyone who’s faced an HIV diagnosis knows the weight of every decision, especially when it comes to starting a family or learning about a pregnancy. HIV-positive women count on antiretroviral medications like darunavir to protect their own health and lower the risk of passing the virus to their babies. But many people struggle with the question—does darunavir belong in a pregnancy plan?
I’ve sat across from expectant mothers who worry every day about harm to their unborn child, even as they fight for their own health. In clinics, doctors choose treatments based on years of hard evidence and daily experience, not only piles of studies. Darunavir, by itself, has not shown a clear record of birth defects. The Antiretroviral Pregnancy Registry tracks thousands of cases: so far, no pattern of birth defects stands out with darunavir. The World Health Organization and American HIV guidelines both consider darunavir, combined with ritonavir (which boosts its levels), as an option during pregnancy, especially if resistance or side effects rule out other drugs.
Words like “safe” rarely enter the conversation. Tradeoffs and risks define complex care. During studies, darunavir levels can drop in the blood during pregnancy. Bodies change fast—kidneys and livers handle drugs differently. On top of that, not every clinic has labs to frequently check these drug levels. A lower dose sometimes leads to less virus control, meaning moms risk passing HIV to their babies. So careful monitoring and possibly higher doses through pregnancy become essential.
Plenty of mothers never see a specialist, and confusion about medications turns small doubts into problems. In some places, darunavir comes as the only available choice because of resistance, cost, or limited supplies. Pregnant women may not have the luxury of choosing newer options. Some worry about side effects like nausea or liver strain, which pop up more often with darunavir—but for those already on stable treatment, switching could push the virus up and undo years of control.
Pregnancy alone brings uncertainty; adding HIV and complex drug regimens turns it into a maze. Healthcare teams must weigh every risk, from missing doses to running out of medication. Misinformation, fear, or lack of support often keep people from sticking with their regimens. Women deserve real answers: a single pill won’t make or break a pregnancy, but staying on proven treatment keeps their viral load low and slashes transmission rates below 1%.
Brushing past the science means risking families’ futures. Darunavir may not top every doctor’s list, but for many it stays in the cabinet for good reason. Pregnant women thriving on it before pregnancy often do best sticking with what works. Giving them facts—supported by registry data and years of first-hand outcomes—lets them make informed choices instead of chasing rumors online.
The best solution puts mothers at the center, with routine lab monitoring, clear public health guidance, and honest dialogue. Funding more research on antiretrovirals in pregnancy and making specialty care accessible, even in small towns, should become priorities. In every appointment, honesty about risks matters more than perfect safety. This way, more parents raise healthy kids without losing their own health fighting for it.
Darunavir helps people with HIV live longer, healthy lives. It’s easy to think about it as just one more pill to take, but this medication has a knack for picking fights with other drugs. Those run-ins can pull down the power of Darunavir or even cause different side effects that feel worse than the original issue. Every day, I meet folks who juggle a handful of prescriptions. Someone always wonders if their normal routine—maybe a cholesterol pill before breakfast, an allergy tablet in the afternoon—could trip up their HIV meds. Turns out, they’re asking the right question.
Darunavir works as part of a class called protease inhibitors. The body depends on certain enzymes, especially one called CYP3A4, to process these drugs. If something blocks or speeds up that enzyme, it messes with how much Darunavir stays in your body. This isn’t just science. Anyone who’s ever eaten a grapefruit and wondered why doctors get jumpy will know: food and medicine often use the same metabolic “roads,” causing jams or dangerous shortcuts.
Let's look at a few usual suspects that health workers and patients need to watch out for:
People come to me worried about their medicine cabinets turning into a chemistry set. While phone apps have made it easier to check for problems, I still see folks surprised by an over-the-counter pill or a supplement their friend swears by. Doctors and pharmacists have drug-interaction databases, but patients really win when they keep an up-to-date medication list and ask questions every single time something new comes along. Real trust grows not from telling someone “Don’t worry,” but from showing exactly where the danger lies.
Managing HIV means playing defense with every drug you take, not just targeting the virus. Every safe day builds on honest questions, clear answers, and a willingness to treat every pill with a little respect.
| Names | |
| Preferred IUPAC name | (3R,3aS,6aR)-hexahydrofurol[2,3-b]furan-3-yl (4S)-4-{[(2S)-2-[(4-aminophenyl)sulfonylamino]-3-methylbutanoyl]amino}-3-hydroxy-4-phenylbutanoate |
| Other names |
Prezista TMC114 |
| Pronunciation | /dəˈruː.nə.vɪr/ |
| Identifiers | |
| CAS Number | 206361-99-1 |
| Beilstein Reference | 3582337 |
| ChEBI | CHEBI:68849 |
| ChEMBL | CHEMBL1201197 |
| ChemSpider | 71780270 |
| DrugBank | DB01264 |
| ECHA InfoCard | 07b42a7b-17c1-42de-bf30-5c6bd6aea58d |
| EC Number | EC 3.4.23.16 |
| Gmelin Reference | 958021 |
| KEGG | D01736 |
| MeSH | D017121 |
| PubChem CID | 213039 |
| RTECS number | YQ7G1U4U5V |
| UNII | N7U69T42KT |
| UN number | UN3248 |
| CompTox Dashboard (EPA) | DTXSID7020182 |
| Properties | |
| Chemical formula | C27H37N3O7S |
| Molar mass | 547.66 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 0.9 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 2.2 |
| Vapor pressure | 5.97E-17 mmHg |
| Acidity (pKa) | 13.31 |
| Basicity (pKb) | 2.80 |
| Magnetic susceptibility (χ) | -72.0 × 10^-6 cm³/mol |
| Dipole moment | 5.22 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 347.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -742.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -9228.8 kJ/mol |
| Pharmacology | |
| ATC code | J05AE10 |
| Hazards | |
| Main hazards | May cause allergy or asthma symptoms or breathing difficulties if inhaled. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | healthcare, prescription, tablet, antiviral, HIV, medicine, pill, bottle, virus, infection, pharmacy |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | P201, P202, P264, P270, P280, P308+P313, P405, P501 |
| Flash point | 100.1 °C |
| Lethal dose or concentration | Lethal dose or concentration (LD50) for Darunavir: "LD50 (rat, oral) >2000 mg/kg |
| LD50 (median dose) | Greater than 2000 mg/kg (oral, rat) |
| PEL (Permissible) | Not established |
| REL (Recommended) | 800 mg once daily |
| IDLH (Immediate danger) | IDLH is not established for Darunavir. |
| Related compounds | |
| Related compounds |
Amprenavir Fosamprenavir Indinavir Lopinavir Ritonavir Saquinavir |
